



# AURIGENE

PHARMACEUTICAL SERVICES



## Drug Metabolism and Pharmacokinetics (DMPK)

Customized and innovative solutions for standalone DMPK and integrated drug discovery services with quick turnaround times

Expertise in **integrated drug discovery** and **standalone DMPK** services

Highly qualified scientists with successful track record

Validated protocols and customized study designs catering to client/project requirements

State-of-the-art ***in vitro*** ADME and tissue culture labs

AAALAC accredited animal facility for ***in vivo*** PK studies in rats, mice and dogs

GLP and Non-GLP bioanalytical labs with high-end LC-MS/MS instruments

 /AurigenePharma

 /aurigenepharmaceuticalservices

 /AurigenePharmaceuticalServices

 [www.aurigeneservices.com](http://www.aurigeneservices.com)

 [contactapsl@aurigeneservices.com](mailto:contactapsl@aurigeneservices.com)

 North America: +1 617 821 0595


 European Union: +32 471 808710

## DMPK Capabilities

- *In vitro* ADME studies: Capable of high-throughput screening with best in industry turnaround times
- *In vivo* PK studies: Established surgical models, microsampling, discrete or cassette designs, PK in various matrices for different therapeutic indications
- Bioanalysis of small molecules, PROTACs, therapeutic peptides and biomarkers. Highly sensitive bioanalysis methods for low dose PK studies
- Automated compound management and data handling systems

## Broad-panel of *In vitro* ADME studies

- **Physicochemical properties:** Solubility & chemical stability at different pH, SIF and SGF to replace with solubility & chemical stability at different pH and matrices  
Solubility: Kinetic, thermodynamic  
HT logD and ChromLogD
- **Permeability:** Caco-2 bi-directional permeability, efflux ratio, MDCK, MDCK-LE, MDCK-MDR1, MDCK-BCRP permeability, PAMPA
- **Distribution:** Plasma protein, *In vitro* tissue binding, blood to plasma partition, brain to plasma partition
- **Metabolism:** Microsomal clearance, S9, phase I/phase II, hepatocyte clearance, plasma/whole blood stability, CYP phenotyping
- **Drug-Drug interactions:** CYP TDI, kobs, CYP induction, P-gp and BCRP inhibition & substrate identification





## Why Aurigene Pharmaceutical Services?



Quick turnaround times



Broad panel of *in vitro* ADME assays and *in vivo* PK study designs



Quality & accuracy, customized protocols



Bioanalysis of small molecules, therapeutic peptides, biomarkers and complex molecules



Compound management and data automation



Flexible business models and quick adaptability to customer requirements



 /AurigenePharma

 /aurigenepharmaceuticalservices

 /AurigenePharmaceuticalServices

 [www.aurigeneservices.com](http://www.aurigeneservices.com)

 [contactapsl@aurigeneservices.com](mailto:contactapsl@aurigeneservices.com)

 North America: +1 617 821 0595

 European Union: +32 471 808710